Condition
Hypogonadism, Hypogonadotropic
Total Trials
5
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 4 (1)
Trial Status
Active Not Recruiting1
Terminated1
Completed1
Enrolling By Invitation1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03490513Phase 4CompletedPrimary
Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism
NCT04733274Active Not RecruitingPrimary
Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing
NCT06691815Not ApplicableEnrolling By Invitation
Triptorelin for Early Diagnosis of Hypogonadotrophic Hypogonadism
NCT04927676Unknown
Hormones in Hypogonadotropic Hypogonadism
NCT03245827Phase 2TerminatedPrimary
Hypogonadotropic Hypogonadism in Obese Young Males
Showing all 5 trials